Memorial Sloan Kettering Cancer Center is recruiting patients for a PHASE2 clinical trial testing HIPEC (heated intraperitoneal chemotherapy) for mesothelioma.
The trial, designated NCT06057935, aims to enroll up to 64 participants at 13 sites, including locations in Illinois, Michigan, Missouri.
About the Study
The purpose of this study is to find out whether intraperitoneal or intravenous chemotherapy given after cytoreductive surgery and HIPEC are effective treatments for people with malignant peritoneal mesothelioma. Outcomes will be compared by observing intraperitoneal versus intravenous treatments to analyze if one is better than the other.
Treatment Approach
This trial uses heated chemotherapy delivered directly into the abdominal cavity during surgery.
Key trial details:
- Phase: PHASE2
- Sponsor: Memorial Sloan Kettering Cancer Center
- Enrollment target: 64
- Status: RECRUITING
Why This Trial Matters
HIPEC has shown promise for peritoneal mesothelioma, with some patients achieving long-term survival when combined with cytoreductive surgery.
Memorial Sloan Kettering is one of the leading mesothelioma treatment centers in the United States.
Study Locations
The trial is recruiting at:
- University of Chicago (Data Collection Only), Illinois
- University of Michigan (Data Collection Only), Michigan
- Washington University (Data Collection Only), Missouri
- University of Nebraska (Data collection only), Nebraska
- Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), New Jersey
How to Enroll
Patients interested in this trial should:
- Discuss eligibility with their oncologist
- Review the full eligibility criteria on ClinicalTrials.gov
- Contact the study coordinator for screening